DOTATOC

Small molecule

TTurku University Hospital

DOTATOC is one of 52 small molecule programs targeting Malignant Glioma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant GliomaActive, not recruiting

Malignant GliomaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

199 competitors in Malignant Glioma

#DrugCompanyPhaseTrials

Bicnu

MMelissa K Accordino

Phase 3

9 2

Ceenu

AAzurity Pharmaceuticals

Phase 3

4 3

Oncovin

EEastern Cooperative Oncology Group

Phase 3

1 4

Thalomid

Bristol-Myers Squibb

Phase 2

3 5

Camptosar

Pfizer

Phase 2

3 6

Avastin

BBio-Thera Solutions

Phase 2

12 7

Sutent

Pfizer

Phase 2

2 8

Leukine

Sanofi

Phase 2

2 9

Zofran

Novartis

Phase 2

2 10

Imjudo

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Malignant Glioma1 trial

Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT

Completed·TTurku University Hospital·Phase 2/3·NCT01460706·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DOTATOC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DOTATOC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DOTATOC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Turku University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: TTurku University Hospital

DOTATOC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Malignant Glioma1 trial

References

Drug Info

Quick Facts

Related News